Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$3.00 - $4.00
Shares Offered
3,333,334
Deal Size
$11.67M

Company Description

Apimeds Pharmaceuticals US is a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects.

Apimeds is currently developing Apitox as a potential osteoarthritis treatment for patients with knee pain who failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.

Apitoxin has been used in the South Korea to treat the reduction of pain associated with OA since 2003 and now we will be pursuing a second Phase III trial to meet agreed upon FDA standards.

Upon the successful completion of our Phase III trial demonstrating therapeutic effect and extended safety data for the use of Apitox to treat pain and mobility in patients with knee OA, we intend to submit a Biologics License Application for Apitox.

Apimeds Pharmaceuticals US, Inc.
Country United States
Founded 2020
Industry Biotechnology
Sector Healthcare
Employees 2
CEO Erik Emerson

Contact Details

Address:
2 East Broad Street 2nd Floor
Hopewell, NJ 08425
United States
Phone 925-872-6429
Website apimedsus.com

Stock Details

Ticker Symbol APUS
Exchange NYSEAMERICAN
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001894525
Employer ID 85-1099700
SIC Code 2834

Key Executives

Name Position
Dr. Christopher Kim, MD Chairman and Chief Medical Officer
Erik Emerson Chief Executive Officer and Chief Financial Officer
Jakap Koo Director
Dr. Bennett Weintraub, PhD. Director
Hankil Yoon Director
Carol O’Donnell Director

Latest SEC Filings

Date Type Title
Dec 20, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Dec 9, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Nov 8, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Sep 25, 2024 S-1 General form for registration of securities under the Securities Act of 1933
Aug 5, 2024 DRS/A [Amend] [Cover] Draft Registration Statement
Jun 17, 2024 DRS/A [Amend] [Cover] Draft Registration Statement
May 13, 2024 DRS/A [Amend] [Cover] Draft Registration Statement
Jan 29, 2024 DRS [Cover] Draft Registration Statement